On September 9, 2021 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that it will host a virtual Investor Day on Friday, September 17, 2021, starting at 9:00 a.m. and expected to conclude by 11:00 a.m. (EDT) (Press release, Thermo Fisher Scientific, SEP 9, 2021, View Source [SID1234587566]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The virtual format will feature presentations by members of Thermo Fisher Scientific’s senior management team and conclude with a Q&A session.

You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com. A replay of the webcast will be available following the presentation.

On September 9, 2021 Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, reported that Feng Tian, Ph.D., President and Chief Executive Officer of Ambrx, will participate in a virtual panel discussion at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place September 13-15, 2021 (Press release, Ambrx, SEP 9, 2021, View Source [SID1234587557]). The discussion will be led by Michael King, Managing Director and Senior Biotechnology Analyst at H.C. Wainwright.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Discussion Topic: Engineered Cytokines: The Next Big Wave in Immuno-Oncology.
Date and Time: Tuesday, September 14, 2021, at 1:30 pm EDT, 10:30 am PDT.

Individuals interested in listening to the panel discussion may do so using the webcast link under "Latest Events" in the Investors section of the company’s website at: www.ambrx.com.

On September 9, 2021 ITM AG, a leading radiopharmaceutical company, reported that it will host a virtual industry satellite symposium titled, "A Global Perspective on the Management of Neuroendocrine Tumors – the Evolving Role of Targeted Radionuclide Diagnostics and Therapy" at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2021 (Press release, ITM Isotopen Technologien Munchen, SEP 9, 2021, View Source [SID1234587556]). The symposium will feature renowned key opinion leaders in the field and will be held on Friday, September 17th, 2021, from 10:30 am – 12:00 pm CEST on channel 3, open to ESMO (Free ESMO Whitepaper) registered participants.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The speakers are key precision oncology experts and will lead critical discussions addressing the changes within the treatment and diagnosis of neuroendocrine tumors. They will cover a range of topics examining the impact of NET diagnostic paradigms, treatment guidelines, and recent advancements within the clinical studies of Targeted Radionuclide Therapy. In addition to the ongoing COMPETE trial, the new phase III trial COMPOSE, a prospective study in high Grade 2 and Grade 3 gastroenteropancreatic NETs, will be presented. Participants will be able to interact with the speakers in a Q&A session at the end of the event.

Scientific Program and Participating Experts:

Welcome & Introduction
Raj Srirajaskanthan, MD, FRCP King’s College Hospital, London, UK (5 mins)
Changes in the Incidence and Prevalence of NETs – Impact of New Diagnostic Paradigms
Simon Singh, MD, MPH Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada (20 mins)
The Evolution of Guidelines for the Treatment of NETs
Namrata Vijayvergia, MD, FACP Fox Chase Cancer Center, Philadelphia, U.S. (20 mins)
The Role of Targeted Radionuclide Therapy in Clinical Trials
Grace Kong, MBBS (Hons), FRACP, FAANMS Peter MacCallum Cancer Center, Melbourne, Australia (20 mins)
Q&A and Closing Remarks (25 mins)
For further information please visit ITM’s ESMO (Free ESMO Whitepaper) 2021 Symposium website or the official ESMO (Free ESMO Whitepaper) webpage.

On September 9, 2021 US Medical Innovations, LLC (USMI), a U.S. FDA-registered life-science and biomedical device company and the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) reported that Jerome Canady MD, CEO will be presenting at the Baird Global Healthcare Conference on Tuesday, September 14th from 10:15 to 10:45 AM ET (Press release, US Medical Innovations, SEP 9, 2021, View Source [SID1234587555]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Canady will present results from their FDA-approved Phase I Clinical Trial evaluating Cold Atmospheric Plasma for the treatment of Stage IV, Recurrent, Metastatic Solid tumors (FDA IDE #190165) and their recent discovery identifying the mechanism in which Canady Helios Cold Plasma induces apoptosis in breast cancer. JCRI-ABTS Discovers the Mechanism using Canady Helios Cold Plasma to Induce Cell Death in Breast Cancer.

The trial was completed April 15, 2021 at Rush University Medical Center (Chicago, IL) and Sheba Medical Center-Tel HaShomer (Ramat Gan, Israel). The Principal Investigators were Professor Steven Gitelis, M.D., and Professor Aviram Nissan, M.D. respectively.

On September 9, 2021 CG Oncology, Inc. reported a clinical trial collaboration to evaluate the safety and efficacy of CG0070, an oncolytic immunotherapy, in combination with OPDIVO (nivolumab), Bristol Myers Squibb’s anti-PD-1 therapy, for the treatment of metastatic urothelial cancer in a Phase 1/2 clinical study (Press release, CG Oncology, SEP 9, 2021, View Source [SID1234587554]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CG0070, CG Oncology’s lead immuno-oncology candidate, is in an ongoing Phase 3 monotherapy study and has been administered in over 100 patients to date for the treatment of high-risk, non-muscle invasive bladder cancer (NMIBC). CG0070 is based on a modified adenovirus type 5 backbone that contains a cancer-selective promoter and a GM-CSF transgene, destroying various cancer cells, including bladder tumor cells, through their defective retinoblastoma (Rb) pathway.

"We are excited to initiate this important clinical trial with our lead oncolytic immunotherapy, CG0070, in combination with OPDIVO in metastatic urothelial cancer," said Arthur Kuan, CEO of CG Oncology. "The clinical results to date for CG0070 make it a potential promising agent in bladder cancer and other tumor types, as monotherapy or in combination with immune checkpoint inhibitors."

CG Oncology will sponsor the study and Bristol Myers Squibb will provide nivolumab. Additional details of the collaboration were not disclosed.

OPDIVO is a trademark of Bristol-Myers Squibb Company.